PROGRAM CHAIR
Kimber Simmons, MD, MS
Associate Professor of Pediatrics
Barbara Davis Center for Diabetes
CU Anschutz Medical Campus
Aurora, Colorado
FEATURING
Luis Carale
Boulder, Colorado
PROGRAM OVERVIEW
This educational program is designed to equip healthcare practitioners who care for patients with type 1 diabetes (T1D) with effective strategies for implementing timely screening protocols, including autoantibody screening, to facilitate early T1D diagnosis. Participants will gain expertise in safely integrating immunomodulatory agents into clinical practice while learning to monitor and prevent associated side effects. This distinctive program offers insights from both a diabetes expert and a patient/caregiver, providing a comprehensive perspective on T1D management.
TARGET AUDIENCE
This activity is intended for pediatric endocrinologists, adult endocrinologists, pediatricians, primary care providers, and endocrine nurses. It also includes accessible programming and resources tailored for patients, their families, and the general public. Activities are structured to allow learners to select content most relevant to their professional needs.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Kimber Simmons, MD | Has received consulting fees from Sanofi and Shoreline Biosciences. She has also received research contracts from Sanofi. |
| Luis Carale | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Mike Milano, MD, has nothing to disclose.
- Marissa Mays-Verman, Program Director for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 30, 2025
EXPIRATION DATE: June 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Kimber Simmons, MD, MS
Associate Professor of Pediatrics
Barbara Davis Center for Diabetes
CU Anschutz Medical Campus
Aurora, Colorado
FEATURING
Angela, Jon, and Elijah Alexander
Castle Rock, Colorado
PROGRAM OVERVIEW
This educational program is designed to equip healthcare practitioners who care for patients with type 1 diabetes (T1D) with effective strategies for implementing timely screening protocols, including autoantibody screening, to facilitate early T1D diagnosis. Participants will gain expertise in safely integrating immunomodulatory agents into clinical practice while learning to monitor and prevent associated side effects. This distinctive program offers insights from both a diabetes expert and a patient/caregiver, providing a comprehensive perspective on T1D management.
TARGET AUDIENCE
This activity is intended for pediatric endocrinologists, adult endocrinologists, pediatricians, primary care providers, and endocrine nurses. It also includes accessible programming and resources tailored for patients, their families, and the general public. Activities are structured to allow learners to select content most relevant to their professional needs.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Describe the clinical presentation of T1D in adults compared to children
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 0.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Kimber Simmons, MD | Has received consulting fees from Sanofi and Shoreline Biosciences. She has also received research contracts from Sanofi. |
| Angela, Jon and Elijah Alexander | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Surabhi Dangi-Garimella, PhD, Medical Director for Med Learning Group has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- Mike Milano, MD, has nothing to disclose.
- Marissa Mays-Verman, Program Director for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 30, 2025
EXPIRATION DATE: June 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
